MIRA PHARMACEUTICALS, INC.
For the period ended Jun 30, 2026. Filed Aug 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 12, 2026
MIRA$0.62+0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations (unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenues | $— | $— | $— | $— |
| Operating costs: | ||||
| General and administrative expenses | 450,330 | 1,049,903 | 1,029,028 | 2,540,699 |
| Research and development expenses | 705,789 | 496,197 | 1,230,570 | 810,601 |
| Total operating costs | 1,156,119 | 1,546,100 | 2,259,598 | 3,351,300 |
| Other (expense) income: | ||||
| Interest income | 35,130 | 8,623 | 80,038 | 30,044 |
| Other expense | — | (235) | — | (235) |
| Loss from equity method investment – related party | (87,545) | — | (179,126) | — |
| Total other (expense) income, net | (52,415) | 8,388 | (99,088) | 29,809 |
| Net Loss | (1,208,534) | (1,537,712) | (2,358,686) | (3,321,491) |
| Basic and diluted loss per share | $(0.03) | $(0.09) | $(0.06) | $(0.19) |
| Basic weighted average common stock shares outstanding | 42,022,087 | 16,986,488 | 41,981,952 | 17,360,272 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.